echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Combination medication has a significant effect on patients with malignant peritoneal mesothelioma

    Combination medication has a significant effect on patients with malignant peritoneal mesothelioma

    • Last Update: 2021-08-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Houston - The second phase of the study by researchers at the University of Texas MD Anderson Cancer Center found that atezolizumab and bevacizumab treatments were well tolerated and resulted in an objective response rate of 40% in the abdomen of patients with advanced malignant peritoneal mesothelioma Rare cancer of the inner layer


    The test results show that the combination therapy is safe and effective for patients with disease progression or intolerance to previous chemotherapy


    Malignant peritoneal mesothelioma (MPeM) is a rare but aggressive disease with historically poor survival and limited treatment options


    "The needs of patients with peritoneal mesothelioma are seriously unmet," Raghav said


    One of the first trials for mpm patients 

    Researchers estimate that 300-500 Americans are diagnosed with multiple polio every year


    There are many treatment strategies, but they usually include the best cytoreduction surgery, intraoperative hypothermic intraperitoneal infusion chemotherapy (HIPEC), or early postoperative intraperitoneal chemotherapy (EPIC)


    The National Comprehensive Cancer Network (NCCN) recommends two first-line platinum chemotherapy for mesothelioma, but after the disease progresses, there is no definite treatment strategy or any FDA-approved treatment for advanced MPeM


    This single-center study is a multi-cohort basket trial to evaluate the efficacy of atezolizumab and bevacizumab in various advanced cancers


    Before participating in this clinical trial, patients who received standard-of-care chemotherapy progressed to the next treatment after 8.


    The 1-year progression-free survival rate and overall survival rate were 61% and 85%, respectively


    Raghav said: "The efficacy of this therapy has exceeded the expectations of traditional therapies


    Biomarker analysis 

    The integration of biopsy before and during treatment establishes the practicality and value of rare cancer transformation motivation methods


    Biomarker analysis identified epithelial-mesenchymal transition (EMT) gene expression, a cancer state associated with more aggressive biology, associated with aggressive disease, treatment resistance, and poor response rates


    To determine the predictive response of the tumor environment to this drug treatment, the researchers used 15 patient samples to examine the subset of immune cells before treatment


    "I am very encouraged by the response to this treatment, and I hope that with more research, this will provide these patients with better treatment options," Raghav said


    More patients are needed to participate in trials to validate these findings and determine whether this drug combination can be used as a first-line treatment or to improve the surgical outcome of these patients


    # # #


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.